Assembly Biosciences (ASMB) EBITDA (2010 - 2026)

Assembly Biosciences' EBITDA history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.

• On a quarterly basis, EBITDA fell 14.37% year-over-year to -$11.4 million in Q1 2026; TTM through Mar 2026 was -$13.5 million, a 69.65% increase from a year earlier, with the FY2025 full-year figure at -$12.1 million, up 73.32% from the prior year.
• EBITDA declined to -$11.4 million in Q1 2026 per ASMB's latest filing, from $19.8 million in the prior quarter.
• Across five years, EBITDA topped out at $19.8 million in Q4 2025 and bottomed at -$24.6 million in Q2 2022.
• The 5-year median for EBITDA is -$12.2 million (2024), against an average of -$13.4 million.
• Across the five-year window, EBITDA fell 23.98% in 2022 and surged 271.69% in 2025, its largest moves.
• Year by year, EBITDA stood at -$23.0 million in 2022, then jumped by 45.38% to -$12.6 million in 2023, then increased by 8.12% to -$11.5 million in 2024, then jumped by 271.69% to $19.8 million in 2025, then tumbled by 157.43% to -$11.4 million in 2026.
• Per Business Quant, the three latest ASMB EBITDA figures stand at -$11.4 million (Q1 2026), $19.8 million (Q4 2025), and -$10.9 million (Q3 2025).